EP1332128A1 - Derives benzamidine comportant un groupe sulfate, servant d'antagonistes de ltb4 - Google Patents

Derives benzamidine comportant un groupe sulfate, servant d'antagonistes de ltb4

Info

Publication number
EP1332128A1
EP1332128A1 EP01978439A EP01978439A EP1332128A1 EP 1332128 A1 EP1332128 A1 EP 1332128A1 EP 01978439 A EP01978439 A EP 01978439A EP 01978439 A EP01978439 A EP 01978439A EP 1332128 A1 EP1332128 A1 EP 1332128A1
Authority
EP
European Patent Office
Prior art keywords
group
formula
independently represent
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01978439A
Other languages
German (de)
English (en)
Inventor
Ralf Anderskewitz
Kurt Schromm
Franz Birke
Hans Michael Jennewein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1332128A1 publication Critical patent/EP1332128A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/22—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
    • C07C305/24—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to new sulfooxybenzamides of the formula I
  • Benzamidine derivatives are known from the prior art as active ingredients with valuable pharmaceutical properties.
  • international patent applications WO 97/21670 and WO 98/11062 disclose, inter alia, benzamidines which have free hydroxyl groups.
  • benzamidines containing sulfate groups there is no reference to benzamidines containing sulfate groups.
  • the object of the present invention is to provide new ETB 4 antagonists which, due to their LJB 4 antagonistic properties, have a wide range of possible uses in the therapeutic field.
  • the invention thus relates to sulfooxybenza ide of the general formula 1 in which
  • a J and A 2 each independently for one, optionally by one or more
  • Haloalkyl groups or Ci-Cg-alkoxy groups substituted 1,4-phenylene or
  • Z 1 and Z 2 each independently represent a group of the formula
  • R 1 is hydrogen, hydroxy, -COO-Ci-Cg-alkyl or -COO-C C 4 -alkyl-phenyl, in which in the above Group of the phenyl ring each
  • C 1 -C 4 alkyl or CC alkoxy can be substituted, R 2 and R 3 each independently of one another for a hydrogen or halogen atom, or a Ci-Cg-alkyl, C C_-haloalkyl, dC 8 alkoxy, aryl, aryloxy or
  • Aralkyl group, R 4 and R 5 each independently represent hydrogen or CC alkyl, X 1 and X 2 each independently represent -O-, -S-, -NH- or a single bond,
  • X J and X 4 each independently represent -O-, -S-, -NH- or a single bond
  • m and n each independently represent 0 or 1
  • r and s each independently represent an integer from 1 to 8
  • a 1 and A 2 each independently represent a 1,4-phenylene or 1,3-phenylene group which is optionally substituted by a C 1 -C 4 -alkyl group or C 2 -C 4 -alkenyl group,
  • Z 1 and Z 2 each independently represent a group of the formula -X 3 - (CH 2 ) S -X 4 - or a single bond,
  • R ' represents hydrogen
  • R 2 and R 3 each represent a hydrogen atom
  • R 4 and R 5 each independently represent C 1 -C 4 -alkyl
  • X 1 and X 2 each independently represent -O- or a single bond
  • X J and X 4 each independently represent -O- or a single bond
  • m and n each independently represent 0 or 1
  • r and s each independently represent an integer from 1 to 3.
  • a further preferred embodiment is the compounds of the formula I in which Z ° represents a group of the formula -CR 4 R 5 -, A 1 and A 2 each independently represent an optionally substituted by a C ⁇ -C 4 - alkyl group or C 2 -C 4 alkenyl group substituted 1,4-phenylene or 1,3-phenylene group, preferably A is 1,4-phenylene 1 and A 2 1,3-phenylene, Z 1 and Z 2 each independently represent a group of the formula -X 3 - (CH 2 ) S -X 4 -, preferably Z 1 denotes -O-CHz- and Z 2 - CH 2 -O-
  • R 1 represents hydrogen
  • R 2 and R 3 each represent a hydrogen atom
  • R 4 and R 5 each represent methyl
  • X 3 and X 4 each independently represent -O- or a single bond, m and n each represent 1, and s represents 1.
  • 1,4- -phenylene group preferably a 1,4- -phenylene group substituted by a /. -Propyl or AJlyl group,
  • Z 2 represents a single bond
  • R 1 represents hydrogen
  • R 2 and R 3 each represent a hydrogen atom
  • X 1 and X 2 are each independently -O-, m is 0, n is 1, and r 2 is.
  • CC "- alkyl and CC - alkyl generally represents a branched or unbranched hydrocarbon radical having 1 to 4 or 8 carbon atoms, which may optionally be substituted by one or more halogen atoms, preferably fluorine, which are identical to one another or can be different.
  • halogen atoms preferably fluorine
  • C 2 -C 8 alkenyl and C 2 -C 4 alkenyl generally represent a branched or unbranched unsaturated hydrocarbon radical having 2 to 4 or 8 carbon atoms, optionally with one or more halogen atoms, preferably fluorine - Can be substituted, which can be the same or different from each other.
  • the following hydrocarbon radicals may be mentioned as examples:
  • the group - (CH 2 ) r - or - (CH 2 ) S - means a branched or unbranched double-bonded hydrocarbon bridge with 1 to 8 carbon atoms, which can optionally be substituted by one or more halogen atoms, preferably fluorine, which can be the same or different from one another.
  • Aryl generally represents an aromatic radical having 6 to 10 carbon atoms, preferably phenyl, the aromatic having one or more lower alkyl group (s), lower alkenyl group (s), trifluoromethyl group (s), cyano group (s), alkoxy group (s), nitro group (n), amino group (s) and / or one or more halogen atom (s) - mutually identical or different - can be substituted;
  • the preferred aryl radical is an optionally substituted phenyl radical, halogen - such as fluorine, chlorine or bromine - and hydroxyl being preferred as substituents.
  • Alkoxy generally represents a straight-chain or branched hydrocarbon radical with 1 to 8 carbon atoms bound via an oxygen atom.
  • a lower alkoxy radical having 1 to 3 carbon atoms is preferred.
  • the methoxy group is particularly preferred.
  • Aryloxy generally represents an aromatic radical having 6 to 10 carbon atoms, preferably phenoxy, which is bonded via an oxygen, the aromatic having one or more lower alkyl group (s), lower alkenyl group (s), trifluoromethyl group (s), cyano group (s), alkoxy group ( n), nitro group (s), amino group (s) and / or one or more halogen atom (s) - mutually identical or different - can be substituted; the preferred aryl radical is an optionally substituted phenyl radical, halogen - such as fluorine, chlorine or bromine - and hydroxyl being preferred as substituents.
  • Aralkyl generally represents an aromatic radical having 6 to 10 carbon atoms, preferably phenylalkyl, bonded via an alkylene group, the aromatic group having one or more lower alkyl group (s), lower alkenyl group (s), trifluoromethyl group (s), cyano group (s), alkoxy group ( n), nitro group (s), amino group (s) and / or one or more halogen atom (s) - mutually identical or different - can be substituted; the preferred aryl radical is an optionally substituted phenyl radical, halogen - such as fluorine, chlorine or bromine - and hydroxyl being preferred as substituents.
  • the alkylene group is usually a double-bonded hydrocarbon bridge with 1 to 8 carbon atoms, preferably 1 to 3 carbon atoms, optionally with one or more
  • Halogen atom (s) - preferably fluorine - may be substituted, which may be the same or different from one another.
  • Very particularly preferred compounds are those of the formulas 1A and IB,
  • the compounds IA and IB can arise in vivo as metabolites of a corresponding LTB4-antagonistic compound with a free hydroxy group and have the following Kj values in the receptor binding test:
  • the compounds of the formula I are distinguished by a wide range of possible uses in the therapeutic field. Emphasis should be placed on those applications for which the LTB4 receptor antagonistic properties play a role.
  • the following are particularly worth mentioning: arthritis, asthma, chronic obstructive pulmonary diseases, such as chronic bronchitis, psoriasis, ulcerative colitis, gastro- or enteropathy induced by non-steroidal anti-inflammatory drugs, cystic or pulmonary fibrosis, Alzheimer's disease, shock, reperfusion damage / ischemic heart attack or stroke , Atherosclerosis, multiple sclerosis, autoimmune diseases, malignant neoplasia, alveolitis
  • the new compounds can also be used to treat diseases or conditions in which the passage of cells from the blood via the vascular endothelium into the tissue is important (for example metastasis) or diseases and conditions in which the combination of LTB4 or another active substance (for example 12-HETE) with the LTB4 receptor has an influence on cell proliferation (for example chronic mye
  • the new compounds can also be used in combination with other active ingredients, such as those used for the same indications, or e.g. With
  • Antihistamines PDE4 inhibitors, peptido-leukotriene antagonists and / or PAF-
  • Antagonists. Administration can be topical, oral, transdermal, nasal, parenteral or inhalative. Tests such as those in WO 93/16036, pp. 15 to 17, for example, are suitable for the pharmacological and biochemical investigation of the effects on the content
  • the therapeutic or prophylactic dose depends - apart from the potency of the individual compounds and the body weight of the patient - on the
  • the dose is between 10 and 500 mg, preferably between 20 and 250 mg.
  • between about 0.5 and 25, preferably between about 2 and 20 mg of active ingredient are administered to the patient.
  • Inhalation solutions generally contain between about 0.5 and 5% active ingredient.
  • the new compounds can be administered in customary preparations, for example as tablets, dragées, capsules, wafers, powders, granules, solutions, emulsions, syrups, inhalation aerosols, ointments, suppositories
  • Active ingredient according to the invention 20 parts by weight
  • the ingredients are processed in the usual way to tablets of 500 mg weight.
  • the active substance content can be increased or decreased and the amount of glucose reduced or increased accordingly.
  • Active ingredient according to the invention 100 parts by weight
  • the ingredients are processed in the usual way into suppositories weighing 1.7 g.
  • Micronized active ingredient powder (compound of the formula I; particle size approx. 0.5 to 7 ⁇ m) is filled into hard gelatin capsules in an amount of 5 mg, optionally with the addition of micronized lactose.
  • the powder is extracted from conventional inhalation devices, e.g. according to DE-A 33 45 722, to which reference is hereby made, inhaled.
  • the compounds according to the invention are prepared by methods which are known per se from the prior art. So the connections of the general Formula I can be prepared in such a way that the hydroxyl-containing benzamides of the formula II known for example from the international patent applications WO 97/21670 and WO 98/1 1062
  • X is a leaving group which can be substituted by a phenol oxygen, preferably a halogen atom, in particular chlorine, preferably in the presence of a weak base and a metal iodide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne de nouveaux sulfooxybenzamides de la formule (I) dans laquelle Z<0> est un groupe choisi parmi les formules -X<1>-(CH2)r-X<2>- et -CR<4>R<5>- ; A<1> et A<2> sont indépendamment l'un de l'autre des groupes 1,4-phénylène ou 1,3-phénylène éventuellements substitués par un ou plusieurs atomes halogène, des groupes C1-C8-alkyl, des groupes C2-C8-alcényl, des groupes C1-C8-haloalkyl ou des groupes C1-C8-alkoxy, Z<1> et Z<2> sont indépendamment l'un de l'autre un groupe de formule -X<3>-(CH2)8-X<4>- ou une liaison simple ; et, m et n sont indépendamment l'un de l'autre 0 ou 1, les restes R<1>, R<2>, R<3>, R<4>, R<5>, X<1>, X<2>, X<3>, X<4>, r et s ayant la signification donnée dans le descriptif. L'invention concerne également des procédés de fabrication des composés selon l'invention, et leur utilisation en tant qu'agents pharmaceutiques, en particulier en tant qu'antagonistes de leucotriène B4(LTB4).
EP01978439A 2000-10-24 2001-10-19 Derives benzamidine comportant un groupe sulfate, servant d'antagonistes de ltb4 Withdrawn EP1332128A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10052333 2000-10-24
DE10052333A DE10052333A1 (de) 2000-10-24 2000-10-24 Neue Sulfooxybenzamide
PCT/EP2001/012127 WO2002034715A1 (fr) 2000-10-24 2001-10-19 Derives benzamidine comportant un groupe sulfate, servant d'antagonistes de ltb4

Publications (1)

Publication Number Publication Date
EP1332128A1 true EP1332128A1 (fr) 2003-08-06

Family

ID=7660637

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01978439A Withdrawn EP1332128A1 (fr) 2000-10-24 2001-10-19 Derives benzamidine comportant un groupe sulfate, servant d'antagonistes de ltb4

Country Status (8)

Country Link
EP (1) EP1332128A1 (fr)
JP (1) JP3917516B2 (fr)
AU (1) AU2002210558A1 (fr)
CA (1) CA2425368C (fr)
DE (1) DE10052333A1 (fr)
MX (1) MXPA03003465A (fr)
PE (1) PE20020542A1 (fr)
WO (1) WO2002034715A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100402494C (zh) * 2005-08-25 2008-07-16 江苏吴中苏药医药开发有限责任公司 肌醇硫酸酯铝及其制备方法和口服组合物、应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
DE602005023797D1 (de) * 2004-07-14 2010-11-04 Inflammation Res Ct Co Ltd Verfahren zur Hemmung von Tumormetastasierung
ATE460173T1 (de) * 2005-07-08 2010-03-15 Leopold Franzens Uni Innsbruck Verwendung von extrakten und inhaltsstoffen aus leontopodium zur steigerung der cholinergen funktion
KR20140011383A (ko) 2011-03-16 2014-01-28 크리에이티브 테라퓨틱스 게엠베하 치환된 디페닐 유도체
US12275687B2 (en) 2017-05-12 2025-04-15 Riken Class A GPCR-binding compound modifier

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59310252D1 (de) * 1992-02-05 2002-01-24 Boehringer Ingelheim Pharma Neue Amiderivate, ihre Herstellung und Verwendung als Arzneimittel mit LTB4-antagonistischer Wirkung
DE19546452A1 (de) * 1995-12-13 1997-06-19 Boehringer Ingelheim Kg Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel
DE19636689A1 (de) * 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0234715A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100402494C (zh) * 2005-08-25 2008-07-16 江苏吴中苏药医药开发有限责任公司 肌醇硫酸酯铝及其制备方法和口服组合物、应用

Also Published As

Publication number Publication date
PE20020542A1 (es) 2002-07-16
CA2425368C (fr) 2008-12-09
AU2002210558A1 (en) 2002-05-06
DE10052333A1 (de) 2002-05-02
WO2002034715A1 (fr) 2002-05-02
JP2004512322A (ja) 2004-04-22
MXPA03003465A (es) 2004-12-06
CA2425368A1 (fr) 2003-04-08
JP3917516B2 (ja) 2007-05-23

Similar Documents

Publication Publication Date Title
EP0902013B1 (fr) Nouveau dérivés de l&#39;amidine, leur fabrication et leur application en tant que médicaments ayant un effet antagoniste à LTB4
EP1203764B1 (fr) Dérivés de benzamidine ayant une activité antagoniste de LTB4
EP0770059B1 (fr) Benzamidines substituees, leur preparation et leur utilisation comme medicaments
DE69427591T2 (de) 7-(2-imidazolinylamino)quinolin-verbindungen als alpha-2 adrenorezeptor-agonisten
EP1015421B1 (fr) Nouveaux derives de phenylamidine, leur procede de preparation et leur utilisation comme medicaments
DE10138273A1 (de) Arzneimittel mit neuroprotektiver Wirkung
EP0770058A1 (fr) Nouveau compose chimique, sa preparation et son utilisation en tant que medicament
DE3855520T2 (de) Methode zur Verbesserung des Schlafes
DE69424183T2 (de) 6-(2-imidazolinylamino)chinolin-verbindungen als alpha-2-adrenoceptor-antagonisten
EP0025192A2 (fr) Acides oxiranne-carboxyliques substitués, procédé pour leur préparation, leur utilisation et médicaments les contenant
EP0163888A1 (fr) Amidinohydrazones de dérivés de tétraline, de chromone, de thiachromone et de tétrahydroquinoléine, procédé pour leur préparation et leur utilisation dans des médicaments
EP0038343B1 (fr) Ceto-acides carboxyliques substitues - procedes de leur preparation - leur utilisation et compositions medicamenteuses les contenant
EP0046961B1 (fr) Acides époxy-cycloalcoylalcanoiques, procédé pour les préparer, leur utilisation et médicaments les contenant
EP0243903A1 (fr) 1-(Oméga[bis-(phényl)alcoxy]-alcoyl) -4-alcénylpipérazines et -4-(alcynyl)-pipérazines respectivement éventuellement substituées, leur procédé de préparation et médicaments qui les contiennent
DE3630903A1 (de) Neue tetrahydronaphthalin- und indanderivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel
EP1332128A1 (fr) Derives benzamidine comportant un groupe sulfate, servant d&#39;antagonistes de ltb4
EP0171645A1 (fr) Dérivés de 2H-1-benzopyran-2-one, procédé pour leur préparation et médicaments les contenant
DE19637123A1 (de) Neue Pyranosidderivate
DE2719576A1 (de) Arzneimittel
EP0980351B1 (fr) Derives de benzylamine et de phenylethylamine, leurs procedes de preparation et leur utilisation comme medicaments
EP0053695A2 (fr) Esters de l&#39;acide N-pyrimidinylcarbamique, leur procédé de préparation et médicaments les contenant
EP0401798A2 (fr) Dérivés substitués d&#39;aminoalkylbenzènes
DE19941540C2 (de) Sulfonylcarboxamide zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidämie
EP1222162B1 (fr) Nouvel antagoniste de ltb4, procede permettant de le preparer et son utilisation comme medicament
DE3640829A1 (de) Neue 1-aryloxy-3-amino-2-propanole, ihre herstellung und verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030526

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

17Q First examination report despatched

Effective date: 20080331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080813